Claims for Patent: 5,550,134

Summary for Patent: 5,550,134

Title:	Methods for inhibiting bone loss
Abstract:	The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.
Inventor(s):	Audia; James E. (Indianapolis, IN), Neubauer; Blake L. (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	08/438,420
Patent Claims:	1. A method of inhibiting bone loss comprising administering to a mammal in need of treatment an effective amount of a compound of formula I ##STR13## wherein R and R.sup.1 both represent hydrogen or combine to form a bond; R.sup.2 represents hydrogen or C.sub.1 -C.sub.3 alkyl; R.sup.3 represents hydrogen, methyl or ethyl; either R.sup.4 and X--R.sup.5 have the following definitions, (R.sup.6).sub.m is absent, and R.sup.3 does not represent hydrogen; or (R.sup.6).sub.m has the following definition, R.sup.4 and X--R.sup.5 are absent, and R.sup.3 does not represent ethyl; R.sup.4 and --X--R.sup.5 each occupies one of the 7-, 8- and 9-positions; R.sup.4 represents hydrogen, halo, methyl or ethyl; x represents C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, a bond, --SO--, --SO.sub.2 --, --CO--Y--(CH.sub.2).sub.n --, --Y--CO--(CH.sub.2).sub.n, --CO--, --Z--(CH.sub.2).sub.n --, or --SO.sub.3 --; wherein X groups which are not symmetrical may be in either orientation; Y represents --S--, --O--, or --NH--; Z represents --O-- or --S--; n represents 0-3; R.sup.5 represents phenyl, naphthalenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, anthracenyl, acenaphthalenyl, thiazolyl, benzimidazolyl, indazolyl, thiophenyl, phenanthrenyl, quinolinyl, fluorenyl, isoquinolinyl, indanyl, benzopyranyl, indolyl, benzisoquinolinyl, benzindolyl, benzothiazolyl, benzothiophenyl, quinoxalinyl, benzoxazolyl, metrazolyl, naphthothiazolyl, quinazolinyl, thiazolopyridinyl, pyridazinoquinazolinyl, benzisothiazolyl, benzodioxolyl, benzodioxinyl, diphenylmethyl or triphenylmethyl; the above R.sup.5 groups are unsubstituted or substituted with 1-3 groups chosen from the group consisting of halo, trifluoromethyl, trifluoroethoxy, C.sub.1 -C.sub.4 alkyl, trifluoromethoxy, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, C.sub.1 -C.sub.3 alkylthio, C.sub.1 -C.sub.6 alkanoyl, phenyl, oxo, phenoxy, phenylthio, C.sub.1 -C.sub.3 alkylsulfinyl, C.sub.1 -C.sub.3 alkylsulfonyl, cyano, amino, C.sub.1 -C.sub.3 alkylamino, diphenylmethylamino, triphenylmethylamino, benzyloxy, benzylthio, (mono-halo, nitro or CF.sub.3)benzyl(oxy or thio), di(C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.6 cycloalkyl, or C.sub.4 -C.sub.8 cycloalkylalkyl)amino, (mono-C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halo)-(phenyl, phenoxy, phenylthio, phenylsulfonyl or phenoxysulfonyl), C.sub.2 -C.sub.6 alkanoylamino, benzoylamino, diphenylmethylamino (C.sub.1 -C.sub.3 alkyl), aminocarbonyl, C.sub.1 -C.sub.3 alkylaminocarbonyl, di(C.sub.1 -C.sub.3 alkyl) aminocarbonyl, halo-C.sub.1 -C.sub.6 alkanoyl, aminosulfonyl, C.sub.1 -C.sub.3 alkylaminosulfonyl, di(C.sub.1 -C.sub.3 alkyl) aminosulfonyl, phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), (halo, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy)phenyl(oxy or thio) (C.sub.1 -C.sub.3 alkyl), benzoyl, or (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino) (C.sub.1 -C.sub.3 alkyl); or an above R.sup.5 group is substituted with a morpholino(C.sub.1 -C.sub.3 alkyl) group, a phenyl(C.sub.1 -C.sub.3 alkyl)piperidinyl group, a phenyl(C.sub.1 -C.sub.3 alkyl)-piperidinylaminocarbonyl group, a C.sub.2 -C.sub.6 alkanoyl-aminothiophenyl group, or a (amino, C.sub.1 -C.sub.3 alkylamino or di(C.sub.1 -C.sub.3 alkyl)amino)naphthalenylsulfonylamino group; or R.sup.5 is a perhalophenyl group; m represents 1-2; R.sup.6 represents hydrogen, halogen, NO.sub.2, cyano, CF.sub.3, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, mercapto, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl, C.sub.1 -C.sub.6 alkylsulfonyl, or a group --A--R.sup.7 where A is C.sub.1 -C.sub.6 alkylene C.sub.2 -C.sub.6 alkenylene or C.sub.2 -C.sub.6 alkynylene; and R.sup.7 represents halogen, hydroxy, CF.sub.3, C.sub.1 -C.sub.6 alkoxy, carboxy, C.sub.1 -C.sub.6 alkoxycarbonyl, amino, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, amido, C.sub.1 -C.sub.4 alkylamido, C.sub.1 -C.sub.4 dialkylamido, C.sub.1 -C.sub.4 alkylsulfonylamino, aminosulfonyl or C.sub.1 -C.sub.4 alkylaminosulfonyl; or a pharmaceutically acceptable salt thereof. 2. A method according to claim 1 wherein said mammal is a human. 3. A method according to claim 2 wherein said human is a female. 4. A method of claim 2 wherein the compound is (-)-(4aR)-(10bR)-8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]qui nolin-3-one. 5. A method of claim 2 wherein the compound is (+)-(4aR)-(10bR)-8-chloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo [f]quinolin-3-one. 6. A method of claim 2 wherein the compound is 8-chloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one 7. A method of claim 2 wherein the compound is (+)-(4aR)-(10bR)-8,9-dichloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrob enzo[f]quinolin-3-one. 8. A method of claim 2 wherein the compound is (+)-(4aR)-(10bR)-4,10b-dimethyl-8-(2-phenylethyl)-1,2,3,4,4a,5,6,10b-octah ydrobenzo[f]quinolin-3-one. 9. A method of claim 2 wherein the compound is (+)-(4aR)-(10bR)-8-benzylthio-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrob enzo[f]quinolin-3-one. 10. A method according to claim 2 wherein said administration is prophylactic. 11. A method for inhibiting bone loss comprising the method of claim 2 and further comprising administering to said human an effective amount of a bone antiresorptive agent. 12. A method according to claim 11 wherein said formula I compound is (-)-(4aR)-(10bR)-8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]qui nolin-3-one, and said bone antiresorptive agent is estrogen, raloxifene, or alendronate. 13. A method according to claim 11 wherein said formula I compound is (+)-(4aR)-(10bR)-8-chloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo [f]quinolin-3-one and said bone antiresorptive agent is estrogen, raloxifene, or alendronate. 14. A method according to claim 11 wherein said formula I compound is 8-chloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]-quinolin-3-on e and said bone antiresorptive agent is estrogen, raloxifene, or alendronate. 15. A method according to claim 11 wherein said formula I compound is (+)-(4aR)-(10bR)-8,9-dichloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrob enzo[f]quinolin-3-one and said bone antiresorptive agent is estrogen, raloxifene, or alendronate. 16. A method according to claim 11 wherein said formula I compound is (+)-(4aR)-(10bR)-4,10b-dimethyl-8-(2-phenylethyl)-1,2,3,4,4a,5,6,10b-octah ydrobenzo[f]quinolin-3-one and said bone antiresorptive agent is estrogen, raloxifene, or alendronate. 17. A method according to claim 11 wherein said formula I compound is (+)-(4aR)-(10bR)-8-benzylthio-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrob enzo[f]quinolin-3-one and said bone antiresorptive agent is estrogen, raloxifene, or alendronate. 18. A method for inhibiting bone loss comprising the method of claim 2 and further comprising administering to said human an effective amount of a bone anabolic agent. 19. A method according to claim 18 wherein said formula I compound is (-)-(4aR)-(10bR)-8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]qui nolin-3-one and said bone anabolic agent is parathyroid hormone (1-84) or (1-34). 20. A method according to claim 18 wherein said formula I compound is (+)-(4aR)-(10bR)-8-chloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo [f]quinolin-3-one and said bone anabolic agent is parathyroid hormone (1-84) or (1-34). 21. A method according to claim 18 wherein said formula I compound is 8-chloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolin-3-one and said bone anabolic agent is parathyroid hormone (1-84) or (1-34). 22. A method according to claim 18 wherein said formula I compound is (+)-(4aR)-(10bR)-8,9-dichloro-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrob enzo[f]quinolin-3-one and said bone anabolic agent is parathyroid hormone (1-84) or (1-34). 23. A method according to claim 18 wherein said formula I compound is (+)-(4aR)-(10bR)-4,10b-dimethyl-8-(2-phenylethyl)-1,2,3,4,4a,5,6,10b-octah ydrobenzo[f]quinolin-3-one and said bone anabolic agent is parathyroid hormone (1-84) or (1-34). 24. A method according to claim 18 wherein said formula I compound is (+)-(4aR)-(10bR)-8-benzylthio-4,10b-dimethyl-1,2,3,4,4a,5,6,10b-octahydrob enzo[f]quinolin-3-one and said bone anabolic agent is parathyroid hormone (1-84) or (1-34).

Details for Patent 5,550,134

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26